Does the media prefer CYTK or RVMD?

In the previous week, Revolution Medicines had 7 more articles in the media than Cytokinetics. MarketBeat recorded 16 mentions for Revolution Medicines and 9 mentions for Cytokinetics. Revolution Medicines' average media sentiment score of 0.64 beat Cytokinetics' score of 0.36 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Revolution Medicines 4 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CYTK or TEVA?

In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than Cytokinetics. MarketBeat recorded 17 mentions for Teva Pharmaceutical Industries and 9 mentions for Cytokinetics. Teva Pharmaceutical Industries' average media sentiment score of 1.00 beat Cytokinetics' score of 0.36 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Teva Pharmaceutical Industries 12 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CYTK or ONC?

In the previous week, Cytokinetics and Cytokinetics both had 9 articles in the media. BeOne Medicines' average media sentiment score of 0.77 beat Cytokinetics' score of 0.36 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral BeOne Medicines 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MRNA or CYTK more profitable?

Moderna has a net margin of -143.55% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Cytokinetics -784.02% N/A -52.86%

Does the media favor MRNA or CYTK?

In the previous week, Moderna had 15 more articles in the media than Cytokinetics. MarketBeat recorded 24 mentions for Moderna and 9 mentions for Cytokinetics. Moderna's average media sentiment score of 0.77 beat Cytokinetics' score of 0.36 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 11 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to CYTK or ROIV?

In the previous week, Cytokinetics had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 9 mentions for Cytokinetics and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.70 beat Cytokinetics' score of 0.36 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Roivant Sciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cytokinetics (CYTK) Competitors

$84.87 -1.20 (-1.39%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$85.33 +0.46 (+0.54%)

As of 07/10/2026 07:54 PM Eastern

Compare

CYTK vs. RVMD, TEVA, ONC, MRNA, and ROIV

Should you buy Cytokinetics stock or one of its competitors? MarketBeat compares Cytokinetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cytokinetics include Revolution Medicines (RVMD), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Moderna (MRNA), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.

How does Cytokinetics compare to Revolution Medicines?

Cytokinetics (NASDAQ:CYTK) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Cytokinetics has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$105.82M	99.80	-$784.96M	-$6.84	N/A
Revolution Medicines	$11.58M	3,430.97	-$1.13B	-$7.07	N/A

Cytokinetics presently has a consensus price target of $99.90, indicating a potential upside of 17.71%. Revolution Medicines has a consensus price target of $144.00, indicating a potential downside of 22.95%. Given Cytokinetics' higher possible upside, equities analysts plainly believe Cytokinetics is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

Revolution Medicines has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Revolution Medicines	N/A	-83.22%	-59.06%

94.3% of Revolution Medicines shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Revolution Medicines had 7 more articles in the media than Cytokinetics. MarketBeat recorded 16 mentions for Revolution Medicines and 9 mentions for Cytokinetics. Revolution Medicines' average media sentiment score of 0.64 beat Cytokinetics' score of 0.36 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Revolution Medicines	4 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytokinetics has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

Summary

Revolution Medicines beats Cytokinetics on 9 of the 16 factors compared between the two stocks.

How does Cytokinetics compare to Teva Pharmaceutical Industries?

Cytokinetics (NASDAQ:CYTK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Cytokinetics' net margin of -784.02%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than Cytokinetics. MarketBeat recorded 17 mentions for Teva Pharmaceutical Industries and 9 mentions for Cytokinetics. Teva Pharmaceutical Industries' average media sentiment score of 1.00 beat Cytokinetics' score of 0.36 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Teva Pharmaceutical Industries	12 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 2.6% of Cytokinetics shares are held by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cytokinetics presently has a consensus price target of $99.90, indicating a potential upside of 17.71%. Teva Pharmaceutical Industries has a consensus price target of $41.78, indicating a potential upside of 27.29%. Given Teva Pharmaceutical Industries' higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Cytokinetics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

Teva Pharmaceutical Industries has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$105.82M	99.80	-$784.96M	-$6.84	N/A
Teva Pharmaceutical Industries	$17.26B	2.19	$1.41B	$1.33	24.68

Summary

Teva Pharmaceutical Industries beats Cytokinetics on 12 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to BeOne Medicines?

Cytokinetics (NASDAQ:CYTK) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

BeOne Medicines has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$105.82M	99.80	-$784.96M	-$6.84	N/A
BeOne Medicines	$5.34B	6.13	$286.93M	$4.47	66.82

Cytokinetics presently has a consensus price target of $99.90, suggesting a potential upside of 17.71%. BeOne Medicines has a consensus price target of $391.38, suggesting a potential upside of 31.03%. Given BeOne Medicines' higher probable upside, analysts plainly believe BeOne Medicines is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

BeOne Medicines has a net margin of 8.94% compared to Cytokinetics' net margin of -784.02%. BeOne Medicines' return on equity of 12.06% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
BeOne Medicines	8.94%	12.06%	6.69%

48.6% of BeOne Medicines shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Cytokinetics and Cytokinetics both had 9 articles in the media. BeOne Medicines' average media sentiment score of 0.77 beat Cytokinetics' score of 0.36 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
BeOne Medicines	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytokinetics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

Summary

BeOne Medicines beats Cytokinetics on 12 of the 16 factors compared between the two stocks.

How does Cytokinetics compare to Moderna?

Moderna (NASDAQ:MRNA) and Cytokinetics (NASDAQ:CYTK) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Moderna has a net margin of -143.55% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Cytokinetics	-784.02%	N/A	-52.86%

In the previous week, Moderna had 15 more articles in the media than Cytokinetics. MarketBeat recorded 24 mentions for Moderna and 9 mentions for Cytokinetics. Moderna's average media sentiment score of 0.77 beat Cytokinetics' score of 0.36 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	11 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Moderna has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

Moderna presently has a consensus price target of $38.27, suggesting a potential downside of 43.95%. Cytokinetics has a consensus price target of $99.90, suggesting a potential upside of 17.71%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts plainly believe Cytokinetics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

75.3% of Moderna shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 2.6% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cytokinetics has lower revenue, but higher earnings than Moderna. Cytokinetics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$2.20B	12.29	-$2.82B	-$8.15	N/A
Cytokinetics	$105.82M	99.80	-$784.96M	-$6.84	N/A

Summary

Moderna beats Cytokinetics on 9 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to Roivant Sciences?

Cytokinetics (NASDAQ:CYTK) and Roivant Sciences (NASDAQ:ROIV) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

Cytokinetics has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

Roivant Sciences has lower revenue, but higher earnings than Cytokinetics. Roivant Sciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$105.82M	99.80	-$784.96M	-$6.84	N/A
Roivant Sciences	$8.26M	3,132.22	-$299.77M	-$0.60	N/A

Cytokinetics has a net margin of -784.02% compared to Roivant Sciences' net margin of -3,629.19%. Cytokinetics' return on equity of 0.00% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

In the previous week, Cytokinetics had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 9 mentions for Cytokinetics and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.70 beat Cytokinetics' score of 0.36 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Roivant Sciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

64.8% of Roivant Sciences shares are held by institutional investors. 2.6% of Cytokinetics shares are held by insiders. Comparatively, 10.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cytokinetics presently has a consensus target price of $99.90, indicating a potential upside of 17.71%. Roivant Sciences has a consensus target price of $33.59, indicating a potential downside of 6.61%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts clearly believe Cytokinetics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Cytokinetics beats Roivant Sciences on 9 of the 17 factors compared between the two stocks.

Get Cytokinetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYTK vs. The Competition

Export

Metric	Cytokinetics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.56B	$3.71B	$7.08B	$12.66B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-12.41	21.64	27.42	24.51
Price / Sales	99.80	223.15	501.22	86.52
Price / Cash	N/A	61.98	29.24	49.38
Price / Book	-15.75	8.70	10.98	6.43
Net Income	-$784.96M	$23.83M	$3.59B	$331.16M
7 Day Performance	-1.87%	-0.75%	-0.26%	0.35%
1 Month Performance	20.98%	8.68%	4.55%	0.57%
1 Year Performance	129.32%	55.85%	29.86%	22.26%

Cytokinetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYTK Cytokinetics	2.2188 of 5 stars	$84.87 -1.4%	$99.90 +17.7%	+129.3%	$10.56B	$105.82M	N/A	250	News Coverage Analyst Forecast Insider Trade
RVMD Revolution Medicines	1.9632 of 5 stars	$192.62 +5.8%	$132.78 -31.1%	+391.5%	$38.71B	$11.58M	N/A	250	Analyst Forecast
TEVA Teva Pharmaceutical Industries	4.8011 of 5 stars	$33.20 0.0%	$41.78 +25.8%	+100.3%	$38.19B	$17.26B	24.96	33,950	News Coverage Positive News Analyst Downgrade
ONC BeOne Medicines	4.6874 of 5 stars	$289.99 +3.6%	$390.00 +34.5%	+19.3%	$30.71B	$5.74B	64.87	12,000	News Coverage Analyst Forecast Insider Trade
MRNA Moderna	1.8565 of 5 stars	$69.70 +3.6%	$37.13 -46.7%	+102.9%	$26.69B	$1.94B	N/A	4,700	Trending News Analyst Forecast Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYTK) was last updated on 7/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytokinetics (CYTK) Competitors

CYTK vs. RVMD, TEVA, ONC, MRNA, and ROIV

How does Cytokinetics compare to Revolution Medicines?

Summary

How does Cytokinetics compare to Teva Pharmaceutical Industries?

Summary

How does Cytokinetics compare to BeOne Medicines?

Summary

How does Cytokinetics compare to Moderna?

Summary

How does Cytokinetics compare to Roivant Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK vs. The Competition

Cytokinetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytokinetics (CYTK) Competitors

CYTK vs. RVMD, TEVA, ONC, MRNA, and ROIV

How does Cytokinetics compare to Revolution Medicines?

Which has stronger valuation & earnings, CYTK or RVMD?

Do analysts prefer CYTK or RVMD?

Is CYTK or RVMD more profitable?

Do insiders and institutionals have more ownership in CYTK or RVMD?

Does the media prefer CYTK or RVMD?

Which has more risk & volatility, CYTK or RVMD?

Summary

How does Cytokinetics compare to Teva Pharmaceutical Industries?

Is CYTK or TEVA more profitable?

Does the media refer more to CYTK or TEVA?

Do institutionals & insiders believe in CYTK or TEVA?

Do analysts rate CYTK or TEVA?

Which has more volatility & risk, CYTK or TEVA?

Which has better earnings & valuation, CYTK or TEVA?

Summary

How does Cytokinetics compare to BeOne Medicines?

Which has higher valuation and earnings, CYTK or ONC?

Do analysts rate CYTK or ONC?

Is CYTK or ONC more profitable?

Do insiders & institutionals hold more shares of CYTK or ONC?

Does the media refer more to CYTK or ONC?

Which has more volatility & risk, CYTK or ONC?

Summary

How does Cytokinetics compare to Moderna?

Is MRNA or CYTK more profitable?

Does the media favor MRNA or CYTK?

Which has more volatility and risk, MRNA or CYTK?

Do analysts rate MRNA or CYTK?

Do insiders and institutionals have more ownership in MRNA or CYTK?

Which has better valuation and earnings, MRNA or CYTK?

Summary

How does Cytokinetics compare to Roivant Sciences?

Which has more volatility & risk, CYTK or ROIV?

Which has better valuation and earnings, CYTK or ROIV?

Is CYTK or ROIV more profitable?

Does the media refer more to CYTK or ROIV?

Do insiders & institutionals believe in CYTK or ROIV?

Do analysts rate CYTK or ROIV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK vs. The Competition

Cytokinetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools